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Abstract
Background Renal denervation (RDN) may lower blood
pressure (BP); however, it is unclear whether medication
changes may be confounding results. Furthermore, limited
data exist on pattern of ambulatory blood pressure (ABP)
response—particularly in those prescribed aldosterone
antagonists at the time of RDN.
Methods We examined all patients treated with RDN for
treatment-resistant hypertension in 18 UK centres.
Results Results from 253 patients treated with five tech-
nologies are shown. Pre-procedural mean office BP (OBP)
was 185/102 mmHg (SD 26/19; n = 253) and meanElectronic supplementary material The online version of this
article (doi:10.1007/s00392-015-0959-4) contains supplementary
material, which is available to authorized users.
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daytime ABP was 170/98 mmHg (SD 22/16; n = 186).
Median number of antihypertensive drugs was 5.0: 96 %
ACEi/ARB; 86 % thiazide/loop diuretic and 55 % aldos-
terone antagonist. OBP, available in 90 % at 11 months
follow-up, was 163/93 mmHg (reduction of 22/9 mmHg).
ABP, available in 70 % at 8.5 months follow-up, was
158/91 mmHg (fall of 12/7 mmHg). Mean drug changes
post RDN were: 0.36 drugs added, 0.91 withdrawn. Dose
changes appeared neutral. Quartile analysis by starting
ABP showed mean reductions in systolic ABP after RDN
of: 0.4; 6.5; 14.5 and 22.1 mmHg, respectively (p\ 0.001
for trend). Use of aldosterone antagonist did not predict
response (p[ 0.2).
Conclusion In 253 patients treated with RDN, office BP
fell by 22/9 mmHg. Ambulatory BP fell by 12/7 mmHg,
though little response was seen in the lowermost quartile of
starting blood pressure. Fall in BP was not explained by
medication changes and aldosterone antagonist use did not
affect response.
Keywords Hypertension  Sympathetic nervous system 
Catheter ablation  Aldosterone
Introduction
Hypertension contributes to 62 % of all strokes, 49 % of
global heart disease burden and causes an estimated 7.1 mil-
lion deaths a year [1, 2]. In most real-world datasets, however,
fewer than 50 % of subjects are at target despite a range of
pharmacological options. The reasons for this are complex,
but it seems clear that new strategies for the management of
uncontrolled hypertension are required [3, 4].
Reduction of sympathetic outflow is one proposed
alternative to drug treatment for reducing high blood
pressure. Invasive surgical sympathectomy was shown to
lead to significant blood pressure reductions over 70 years
ago; however, this procedure was abandoned due a high
complication rate [5]. Renal artery sympathetic denerva-
tion aims to more selectively abrogate efferent and afferent
sympathetic nerve signals to and from the kidney, to reduce
sympathetic nervous activity and therefore blood pressure
[6, 7].
Early observational data and open-label, randomized
studies suggested substantial reductions in blood pressure
following a single percutaneous procedure [8, 9]. Reduc-
tion in sympathetic tone through RDN also appeared to be
associated with potential beneficial effects on hypertension
end-organ effects and in other conditions where sympa-
thetic drive may modulate the disease condition [10–16].
More recently, a rigorously conducted randomized trial
added renal denervation (RDN) to a stepped anti-hyper-
tensive drug program and demonstrated incremental blood
pressure lowering with RDN [17]. However, a sham-con-
trolled trial of RDN (symplicity HTN-3) failed to meet its
primary efficacy endpoint [18]. The procedure met its
safety endpoint, but similar reductions in blood pressure
were seen between the renal denervation group and the
sham-control group. Secondary sub-analyses of the trial
dataset by the authors have suggested potential con-
founders, principal amongst them being that fewer than
6 % of patients received per-protocol bilateral retrograde
spiral ablation [19].
The efficacy of this technology therefore remains
uncertain and further randomized trials are required. In the
meantime, more data are required on the nature of the
patients who have already undergone the procedure, their
response to treatment and identification of factors that may
affect subsequent blood pressure response. Such data
would better inform the design, conduct and interpretation
of future trials.
This article reports the UK experience with RDN for
treatment-resistant hypertension. It examines the nature of
the blood pressure response seen on ambulatory monitoring
and the impact of drug changes post denervation on the
results. Finally, this study examines the interaction of RDN
with the use of aldosterone antagonists.
Methods
At the time of instigation of the UK Renal Denervation
Affiliation (May 2014), background research by the study
team identified 21 centers that had performed five or more
procedures in the UK. The aim of this study was to give as
complete as possible a representation of the UK national
experience with RDN to date, by collating retrospective
data from all procedures performed on patients with
uncontrolled hypertension.
19 Department of Interventional Radiology, Heart of England
NHS Foundation Trust, Birmingham, UK
20 Sheffield Vascular Institute, Northern General Hospital,
Herries Road, Sheffield S5 7AU, UK
21 University of Birmingham, Birmingham, UK
22 Bristol Heart Institute, University Hospitals Bristol NHS
Foundation Trust, Bristol BS2 8HW, UK
23 Department of Renal Medicine, Royal Devon and Exeter
NHS Foundation Trust, Barrack Road, Exeter EX2 5DW, UK
24 Radiology Department, Queen Elizabeth Hospital
Birmingham, University Hospital Birmingham NHS Trust,
Edgbaston, Birmingham B15 2TH, UK
25 Queen Elizabeth University Hospital, Glasgow G11 6NT, UK
26 Renal Unit, Birmingham Heartlands Hospital, School of
Clinical and Experimental Medicine, University of
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Each center was contacted by email and/or telephone
and invited to participate in the registry. Eighteen of those
centers agreed to contribute and provided the data that form
the basis for this manuscript. These data represent the
results of cases performed for treatment-resistant hyper-
tension, as defined by prior international consensus state-
ments [7] and in accordance with the Joint UK Societies
consensus statement [20]. A small number of cases were
excluded as they were performed for other indications as
part of ongoing clinical trials (e.g. heart failure; sleep
apnea; acknowledged non-compliance with medications).
Anonymized data were collated locally using a spread-
sheet specifically designed for the study and then submitted
to a central coordinating center (Exeter, UK), where it was
analyzed. The project was independent of any financial
support from industry and is an exclusively investigator-led
initiative.
‘Responders’ to RDN are defined according to prior
convention [21], by a reduction in office systolic blood
pressure of C10 mmHg and reduction in daytime ambu-
latory systolic blood pressure fall of C5 mmHg from
baseline to follow-up [18]. Absence of normal nocturnal
dipping profile on pre-procedural ABP was defined as a fall
in nighttime systolic ABP of \10 %. The lattermost BP
readings available are reported.
Data are presented as mean ± standard deviation (SD)
unless stated. Between group variations were analyzed using
Chi Square test for categorical variables and where normality
was demonstrated, a T test or ANOVA were used for con-
tinuous variables. Logistic regression models were used to
examine the interaction of aldosterone antagonist use with
blood pressure response following RDN after adjustment for
factors previously thought to interact with response to RDN
from prior literature. These models were also used to look for
other potential baseline predictors of blood pressure changes
after RDN. A p value of\0.05 was considered statistically
significant. Statistical analyses were performed using SPSS
software v20.0 (SPSS Inc. Chicago, IL).
Results
Results from 253 subjects, treated in 18 centers using five
different technologies, are included in this analysis. These
include Symplicity Flex [n = 204 (81 %)]; Symplicity
Spyral [n = 10 (4 %)]; Boston Vessix [n = 3 (1 %)]; St
Jude Enlightn [n = 26 (10 %)] and Covidien Oneshot
[n = 10 (4 %)]. Mean age of patients was 57 years; 53 %
were female; 88 % Caucasian and 26.5 % were diabetic
(Table 1).
Eighty-six percent of patients were seen in a dedicated
hypertension clinic with each patient being reviewed by an
average of 1.6 hypertension specialists. These included
cardiologists, nephrologists, clinical pharmacologists and
endocrinologists. All patients had anatomical screening of
their renal arteries prior to their RDN procedure.
The majority of patients had pre-procedural ambulatory
blood pressure monitoring performed (73.5 %) and
detailed assessments to rule out secondary hypertension
before the procedure (screening details are shown in
Table 2).
Mean office BP before procedure was 185/102 mmHg
(SD 26/19; n = 253) with an average daytime ambulatory
blood pressure (ABP) of 170/98 mmHg (SD 22/16;
n = 186). Fifty-eight percent of the cohort had loss of
normal nocturnal dipping on ABP. The median number of
antihypertensive drugs prescribed before RDN was 5.0
including 96 % ACEi/ARB; 86 % thiazide or a loop
diuretic and 55 % aldosterone antagonist prescription at the
time of denervation (Tables 3, 4).
Clinical follow-up was available in 90 % of subjects,
with mean duration of office BP follow-up of 11 months.
Mean post-procedural office BP was 163/93 mmHg, rep-
resenting a fall in office BP following RDN of 22/9 mmHg.
ABP data were available in 70 % of cases post-proce-
dure, at a mean follow-up duration of 8.5 months. Average
daytime ABP at the end of follow-up was 158/91 mmHg,
representing a fall in daytime ABP following RDN of
12/7 mmHg. Average number of antihypertensive agents
added per patient was 0.36. Average number of agents
withdrawn per patient was 0.91 (Tables 5, 6). Drug dose
changes appeared to be balanced across the cohort, in terms
of dose escalation and reductions.
Figure 1 shows BP response to RDN according to
quartile of baseline daytime ambulatory systolic BP.
Baseline mean daytime ambulatory systolic BP (ASBP)
Table 1 Demographic data
Demographic data Mean SD
Age 57 11.8
Serum creatinine 93 36.3
eGFR (MDRD method) 69 21.4
BMI 32 6.4
Demographic data n %
Female 133 53
Caucasian ethnicity 223 88.1
Diabetes 67 26.5
Previous CVA/TIA 61 24.1
Previous myocardial infarction 38 15.0
Symptomatic IHD—previous MI/chronic stable angina 58 22.9
Heart failure 12 4.7
Proteinuria 60 23.7
SD standard deviation
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from quartile 1 to 4 was: 142, 162, 176 and 199 mmHg,
respectively. Number of antihypertensive drugs per quartile
did not significantly differ (p[ 0.2). At 8.5 months follow-
up, the mean reductions in daytime ASBP by quartile of
starting daytime ASBP were: 0.4; 6.5; 14.5 and
22.1 mmHg, respectively (p value for quartile trend
\0.001).
Office systolic BP (OSBP) also exhibited significant
falls across each of the four quartiles (p = 0.001 for
quartile trend), but in the lowest quartile, this was not
matched by a statistically significant ASBP response.
Overall, 65 % patients were defined as responders, with a
C10 mmHg fall in OSBP. A similar percentage (62 %) had
a C5 mmHg fall in daytime ASBP.
Use of aldosterone antagonist at the time of RDN did not
predict the degree of blood pressure response (p[ 0.2 as
univariate predictor). This remained the case after adjust-
ment for the following potential confounders: age, gender,
diabetes, estimated glomerular filtration rate (eGFR),
number of drugs taken and starting office blood pressure
(p[ 0.2). There remained no association when ASBP was
substituted for OSBP within the model. The only baseline
characteristic that predicted subsequent fall in BP after
RDN was blood pressure, as measured by office or ABP.
Discussion
This investigator-led study reports the results of RDN
procedures for 253 people with treatment-resistant hyper-
tension, performed in 18 UK specialist centers using five
Table 2 Screening process
Screened by
Mean number of hypertension specialists seen 1.6 SD (0.7)
Nephrologist 115 45 %
Cardiologist 168 66 %
Clinical pharmacologist 91 36 %
Endocrinologist 38 15 %
Screening process
Diet and Lifestyle re-reviewed 250 99 %
Hypertension managed within dedicated hypertension clinic 217 86 %
Pre-procedural renal CTA/MRA 220 87 %
Pre-procedural renal CTA/MRA/USS 253 100 %
Documented screening results for Cushing’s disease 113 45 %
Documented screening results for phaeochromocytoma 202 80 %
Documented screening results for Conn’s syndrome 159 63 %
SD standard deviation
Table 3 Pre-procedural blood pressure
Blood pressure pre-procedure n = 253 SD
Office Systolic BP (mmHg) 185 26
Office Diastolic BP (mmHg) 102 19
Blood pressure pre-procedure n = 186 SD
Daytime systolic ABP (mmHg) 170 22
Daytime diastolic ABP (mmHg) 98 16
Night-time systolic ABP (mmHg) 154 26
Night-time diastolic ABP (mmHg) 86 18
Loss of normal nocturnal dipping profile (%) 58
SD standard deviation
Table 4 Medications taken by the cohort at the time of denervation
Medications at time of denervation
Median number of medications per patient 5
Renin-angiotensin system blockera (%) 96
B-blocker (%) 65
Calcium channel blocker (%) 73
Diuretic (any) (%) 95
Diuretic-aldosterone antagonist (%) 55
Diuretic-thiazide (%) 52
Diuretic-loop (%) 34
Diuretic-amiloride (%) 2
Alpha-blocker (%) 50
Moxonidine (%) 17
Minoxidil (%) 7
Hydralazine (%) 6
Methyldopa (%) 6
Oral nitrate/nicorandil (%) 5
Clonidine (%) 3
a ACE Inhibitor or angiotensin receptor blocker or direct renin
inhibitor
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different technologies. It shows significant reductions in
both office and daytime ambulatory blood pressure of 22/9
and 12/7 mmHg, respectively, after a mean follow-up
period of 11 months (p\ 0.001 for both findings). This
blood pressure reduction does not appear to be related to
changes in anti-hypertensive medications made after den-
ervation and use of aldosterone antagonists did not affect
blood pressure response following the procedure. Patients
in the two highest quartiles of daytime ambulatory systolic
blood pressure at baseline exhibited significant ambulatory
blood pressure reductions, whilst those in the lowest
quartile exhibited little response.
To date, in excess of 10,000 patients worldwide have
been treated with renal artery denervation [22]. Observa-
tional studies and open-label randomized controlled studies
have suggested significant falls in blood pressure following
treatment, with a particularly well-designed study
(DENER-HTN) suggesting incremental benefit from RDN
when applied over and above stepped anti-hypertensive
therapy [9, 17, 23]. However, a randomized, sham-con-
trolled trial (Symplicity HTN-3) failed to meet its primary
efficacy endpoint, with blood pressure reductions in the
denervated group matched by blood pressure falls in the
sham-control arm [18].
There has been extensive commentary to date on the
possible reasons why HTN-3 failed [22, 24, 25]. The first
Table 5 Follow-up blood pressure data
Mean SD
Follow-up office BP data (n = 228; 90 %)
Duration of follow-up 11.0 6.7
Systolic BP 163 28
Diastolic BP 93 19
Mean fall in cohort office SBP (mmHg) 22 29
Mean fall in cohort office DBP (mmHg) 9 19
Follow-up ABP data (n = 177; 70 %)
Duration of follow-up 8.5 4.0
Daytime systolic BP 158 25
Daytime diastolic BP 91 17
Night-time systolic BP 145 26
Night-time diastolic BP 83 17
Mean fall in cohort daytime systolic ABP (mmHg) 12
Mean fall in cohort daytime diastolic ABP (mmHg) 7
SD standard deviation
Table 6 Drug changes
following RDN procedure
n %
Drugs added since procedure
0 165 65
1 42 17
2 15 6
3 2 1
4 1 0
Data not available 28 11
Drugs stopped since procedure
0 127 50
1 45 18
2 26 10
3 10 4
4 11 4
5 3 1
6 2 1
7 1 0
Data not available 28 11
Average number of anti-hypertensive drugs added since procedure (per patient) 0.36
Average number of anti-hypertensive drugs stopped since procedure (per patient) 0.91
Drug dose changes
Average number of drug doses up-titrated per patient 0.21
Average number of drug doses decreased per patient 0.17
Patients with no changes in drug numbers or drug doses 80
Patients with changes in either drug numbers or drug doses 128
Drug dose changes not available 45
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and most obvious reason is that the technology may be
ineffective. However, the HTN-3 investigators have
recently released data suggesting that the technique used in
HTN-3 may have been sub-optimal, with only 6 % of
subjects treated with the recommended bilateral retrograde
spiral technique [19]. Clearly, sub-optimal denervation
could have confounded the trial [26].
Other commentators have suggested that the failure of
HTN-3 may have been catheter specific [27]. Further
suggestion has been made of the role of ethnicity, the
screening process, drug changes and lack of formal testing
for drug adherence within that trial. These theories repre-
sent post hoc speculation in response to an unexpected
negative result and therefore have to be considered with
caution.
Sound physiological principles and surgical precedent
underpin the field of RDN, which is operating in an area of
medicine with substantial unmet need; the technology
remains promising, appears safe [18, 28–30] and further
randomized trials are required.
In this report, the UK Renal Denervation Affiliation
details the results from 18 centers, each of which had
performed more than five cases to date. Case selection was
typically in accordance with the Joint UK Societies Con-
sensus statement on RDN, which recommended strict
criteria for patient selection [24]. These included:
OSBP[160; systolic ASBP[150 on C3 antihypertensive
agents (or in step 4 of the UK guideline [31]); exclusion of
white-coat or secondary hypertension and patient selection
by multidisciplinary teams of hypertension specialists and
interventionists.
These data present a near-comprehensive national
experience of the use of RDN technology, with over 85 %
of experienced UK centers represented. The mean number
of cases performed per center within this registry was 15
(SD 6.7). By comparison, the mean number of cases per
center in HTN-3 was 4.1 [18].
Results show a fall in office BP of 22/9 mmHg at
11 months. Clearly, such data are open label and therefore
have to be observed with caution, but this is a well
screened and treated cohort, having previously been looked
after by an average of 1.6 specialists with a named interest
in hypertension. More than 85 % of subjects were managed
in dedicated hypertension clinics prior to their denervation
and relatively few drug increases were attempted after their
procedure, despite the severity of their hypertension, sug-
gesting a stable drug regimen was in place prior to their
treatment.
Three times as many drugs were withdrawn following
denervation as were added, with otherwise balanced dose-
Fig. 1 Change in daytime ambulatory systolic blood pressure (ASBP), daytime ambulatory diastolic blood pressure (ADBP), office systolic BP
(SBP) and office diastolic BP (DBP) to RDN by quartile analysis of starting daytime ambulatory SBP
Clin Res Cardiol (2016) 105:544–552 549
123
titrations observed across the cohort. This suggests that
drug changes following RDN may have served to reduce
the observed treatment effect of denervation, rather than
magnify it. Clearly, however, whatever drug regimens were
pursued, office blood pressure is prone to unconscious
confounding, as described by others [32, 33]. Alternate
methods of assessment of the success (or otherwise) of the
technology are required.
Ambulatory blood pressure is a stronger predictor of
outcome than office or home blood pressure readings and a
better measure of true blood pressure than office readings.
It is less prone to variability or confounding and makes
pseudoresistant hypertension unlikely [34].
In this clinical cohort, a high proportion of patients were
assessed using ABP. Some patients could not tolerate the
repeated measures of ABP, which is understandable, given
that some had very high blood pressures (office SBP[240)
at the time of assessment. Despite this, follow-up ABP
results were available in over 70 % of subjects.
Importantly, our cohort showed good pre-procedural
approximation between office and ambulatory BP (pre-
procedural office BP 186/102 mmHg; pre-procedural ABP
of 170/98 mmHg) suggesting little white-coat element
across the cohort.
Furthermore, subjects were prescribed an average of five
medications at the time of their procedure, with a relatively
high use (55 %) of aldosterone antagonists. To our
knowledge, this is the highest proportion of subjects using
aldosterone antagonists in any population of RDN patients
reported to date. Despite these proactive drug strategies,
mean pre-procedural daytime ABP remained
170/98 mmHg, which is, to our knowledge, as severe a
cohort of hypertensives as have been studied with dener-
vation to date.
Prior studies suggest an important role for aldosterone
antagonism in the area of treatment-resistant hypertension
[35]. The recently published PATHWAY-2 trial has con-
firmed spironolactone’s superior efficacy as a ‘step-four’
drug in hypertension pathways, when compared to
B-Blockers and doxazosin. Furthermore, spironolactone
has been proposed as an alternative to denervation, or a
possible synergistic agent in blood pressure reduction fol-
lowing RDN [19, 36–38].
In this UK cohort of subjects, the use of aldosterone
antagonists was not associated with a difference in blood
pressure after RDN but this does not in any way question
the efficacy of spironolactone in a resistant population. In
this population, RDN was reserved for patients who were
resistant to all recommended treatments and therefore we
are observing a ‘treat to target’ effect, whereby other drugs
are being used to compensate for the presence or absence
of a spironolactone effect before a decision on RDN is
made. Aldosterone antagonism use was not randomized
within our cohort and therefore, by definition, the groups
were not balanced and cannot be directly compared for
efficacy of the drug. Rather, we report this to establish
whether spironolactone acts as a predictor of blood pres-
sure fall after RDN and it does not.
The pattern of ABP quartile response to RDN is an
interesting finding from this study. The relationship
between starting office blood pressure and magnitude of
fall in BP has been previously described for office BP and
we replicate this finding with our data. It has been sug-
gested that this could represent a regression to the mean
artefact, but ABPM is more resistant to that bias than office
BP [39]. The large GLOBAL registry has also suggested an
association of starting ABP with magnitude of fall in BP,
but quartiles of response were not reported [29].
Given the strength of the association of fall in ASBP
with ‘true’ starting BP observed in our cohort (as defined
by daytime ASBP) these findings suggest that the most
likely way to demonstrate the effectiveness of RDN in a
randomized, blinded trial, where unconscious confounding
of office response cannot bias the result and treatment
effect sizes tend to be smaller [33], may be to test it in a
cohort of patients with significant hypertension on ABP,
rather than OBP.
Upcoming trials in the field of renal denervation have
been proposed in patients with moderate hypertension
(ABP of 140-170). Such patients most closely approximate
to subjects in quartiles 1 and 2 of our study. Given that
these trials are sham-controlled, we may expect to see
results closer to those of daytime ABP, rather than open-
label office pressure [32]. Rigorous control of potential
confounders will therefore be important to pick up a true
treatment effect size if these BP reductions are replicated.
Given the morbidity and mortality associated with
uncontrolled hypertension, the need for treatment options
over and above medications remains apparent, especially
for those with few remaining medical options. Whilst we
await further randomized trials in this area, results from
this cohort of UK subjects with severe, treatment-resistant
hypertension and few remaining medical options suggest
that, on average, blood pressure control improved follow-
ing RDN, especially in those with ambulatory blood pres-
sure readings in the highest range.
Study limitations
This is an open-label retrospective registry with no outside
funding source and therefore no independent verification of
results was obtained. It is therefore limited by this study
design. However, data quality appeared good, as supported
by the relatively high frequency of reporting of ABP results
and the close correlation between office BP and ABP
results. Results also appear consistent across 18 sites.
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This study did not mandate measures of adherence to
prescribed medications and therefore variable levels of
compliance pre- and post-procedure could have had a
confounding impact on results. However, there is no reason
to suspect changes in behavior occurred according to
starting blood pressure and subjects within each quartile of
starting ABP were prescribed similar numbers of pharma-
cological agents. Recent data have also shown blood
pressure reductions after RDN in proven compliant sub-
jects [40].
Future studies of RDN should, though, incorporate a
direct assessment of adherence, such as urine antihyper-
tensive drug analysis to look for confounding from variable
drug compliance on results. Ultimately, however, novel
measures of blood pressure reduction are needed for both
adherent and non-adherent subjects and both these groups
require study within separate, dedicated, randomized trials.
Reporting of ABP is not universal. ABP was tried in
almost all patients within this cohort, but with a starting BP
of[200 mmHg in many of these patients, the device was
not tolerated for a 24-h period. Furthermore, many of these
subjects travelled long distances to an RDN center for
review and therefore repetition by the performing center
was not feasible. Despite these limitations and the absence
of reimbursement for RDN in the UK, 73 % use is a higher
rate of use of ABP than in other funded registries to date.
Conclusion
This real-world study demonstrates that renal artery sym-
pathetic denervation is associated with a significant
reduction in both office and ambulatory blood pressure in
well-characterized subjects with treatment-resistant
hypertension.
Ambulatory blood pressure reductions were shown to be
greatest in those with the highest starting ambulatory blood
pressures, whilst those with blood pressures in the lowest
quartile of baseline ambulatory blood pressure showed
little response. Use of aldosterone antagonist did not affect
the subsequent blood pressure response after denervation
and drug changes after denervation did not appear to
account for the blood pressure fall seen in the cohort at
follow-up.
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